NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$9.13

+0.20 (+2.24%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.82
▼
$9.14
50-Day Range: $4.43
▼
$9.50
52-Week Range: $3.18
▼
$9.85

Volume: 775,175 shs
Average Volume: 1.09 million shs
Market Capitalization: $796.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.40

Provention Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 134.4% Upside
$21.40 Price Target
Short Interest: Bearish
6.85% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.90
Upright™ Environmental Score
News Sentiment: 0.87
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.66) to ($1.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

366th out of 1,027 stocks

Pharmaceutical Preparations Industry

155th out of 503 stocks

3.5

Analyst's Opinion

Consensus Rating
Provention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.40, Provention Bio has a forecasted upside of 134.4% from its current price of $9.13.
Amount of Analyst Coverage
Provention Bio has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.85% of the outstanding shares of Provention Bio have been sold short.
Short Interest Ratio / Days to Cover
Provention Bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Provention Bio has recently increased by 13.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Provention Bio does not currently pay a dividend.
Dividend Growth
Provention Bio does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Provention Bio has received a 70.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for the autoimmune system" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Provention Bio is -0.90.

3.3

News and Social Media Coverage

News Sentiment
Provention Bio has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Provention Bio this week, compared to 2 articles on an average week.
Search Interest
69 people have searched for PRVB on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.
MarketBeat Follows
19 people have added Provention Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 217% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Provention Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.10% of the stock of Provention Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.39% of the stock of Provention Bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Provention Bio are expected to grow in the coming year, from ($1.66) to ($1.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Provention Bio is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Provention Bio is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Provention Bio has a P/B Ratio of 5.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

December 5, 2022 | finance.yahoo.com

Why Shares of Provention Bio Went Up 30.3% in November

December 1, 2022 | americanbankingnews.com

Provention Bio (NASDAQ:PRVB) Stock Price Down 3.7%

November 25, 2022 | seekingalpha.com

Provention Bio: Assessing The Investment Case After Teplizumab Approval

November 19, 2022 | msn.com

Provention prices diabetes drug above analysts' estimates at $13,850/vial

November 18, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Provention Bio

November 18, 2022 | finance.yahoo.com

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

November 18, 2022 | finance.yahoo.com

Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes

November 18, 2022 | investorplace.com

Provention Bio (PRVB) Stock Falls Despite FDA Approval

November 18, 2022 | reuters.com

Provention Bio diabetes drug to cost $13,850/vial

November 18, 2022 | reuters.com

U.S. FDA greenlights Provention Bio's diabetes drug

November 4, 2022 | seekingalpha.com

Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript

November 3, 2022 | investorplace.com

Why Is Provention Biosciences (PRVB) Stock Up 25% Today?

November 3, 2022 | msn.com

Provention Bio: Q3 Earnings Insights

October 13, 2022 | finance.yahoo.com

Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022

October 12, 2022 | finance.yahoo.com

These 2 Growth Stocks Have Potential Catalysts on the Way

October 6, 2022 | benzinga.com

Thinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?

October 6, 2022 | markets.businessinsider.com

Why Provention Bio Shares Are Skyrocketing Today

October 6, 2022 | msn.com

Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate

October 6, 2022 | nasdaq.com

Provention Bio Announces Collaboration With Sanofi To Expand Commercial Footprint For Teplizumab

October 6, 2022 | finance.yahoo.com

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

September 22, 2022 | finance.yahoo.com

1 Green Flag and 1 Red Flag for Provention Bio

September 19, 2022 | finance.yahoo.com

Provention Bio Announces Senior Leadership Addition

August 12, 2022 | seekingalpha.com

Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating

August 6, 2022 | seekingalpha.com

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings: 11/04/2021
Today: 12/07/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRVB
CUSIP: N/A
CIK: 1695357
Web: www.proventionbio.com
Phone: (908) 428-9136
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.40
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +134.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,430,000.00
Net Margins: -3,791.21%
Pretax Margin: -4,043.30%
Return on Equity: -99.08%
Return on Assets: -76.29%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 7.58
Quick Ratio: 7.58

Sales & Book Value

Annual Sales: $1.39 million
Price / Sales: 572.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.75 per share
Price / Book: 5.22

Miscellaneous

Outstanding Shares: 87,191,000
Free Float: 75,769,000
Market Cap: $796.05 million
Optionable: Not Optionable
Beta: 2.40

Key Executives

Mr. Ashleigh W. Palmer B.Sc. (Age 59)
M.B.A., Co-Founder, Pres, CEO & Director
Comp: $900.3k

Mr. Thierry Chauche (Age 46)
Chief Financial Officer
Comp: $411.37k

Dr. Eleanor L. Ramos M.D. (Age 66)
Chief Medical Officer
Comp: $611.72k

Dr. Francisco Leon M.D. (Age 50)
Ph.D., Co-Founder & Chief Scientific Officer

Ms. Christina Yi (Age 46)
Chief Operations Officer

Mr. Robert A. Doody Jr.
VP of Investor Relations

Ms. Heidy Abreu King-Jones J.D. (Age 39)
L.L.M., Chief Legal Officer

Kaelan Hollon
VP of Corp. Communications

Mr. Jason Levine
VP Marketing

Sarah O'Brien
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings or view top-rated stocks.
What is Provention Bio's stock price forecast for 2023?: 6 Wall Street analysts have issued 12 month price targets for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they predict the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts.
How have PRVB shares performed in 2022?: Provention Bio's stock was trading at $5.62 at the start of the year. Since then, PRVB stock has increased by 62.5% and is now trading at $9.13.
View the best growth stocks for 2022 here.
When is Provention Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRVB earnings forecast.
How were Provention Bio's earnings last quarter?: Provention Bio, Inc. (NASDAQ:PRVB) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative net margin of 3,791.21% and a negative trailing twelve-month return on equity of 99.08%. During the same quarter last year, the firm posted ($0.56) EPS.

What other stocks do shareholders of Provention Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).
What is Provention Bio's stock symbol?: Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."
Who are Provention Bio's major shareholders?: Provention Bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.77%), Vanguard Group Inc. (4.13%), State Street Corp (1.48%), Verition Fund Management LLC (0.99%), Bioimpact Capital LLC (0.85%) and Palo Alto Investors LP (0.45%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends.
How do I buy shares of Provention Bio?: Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Provention Bio's stock price today?: One share of PRVB stock can currently be purchased for approximately $9.13.
How much money does Provention Bio make?: Provention Bio (NASDAQ:PRVB) has a market capitalization of $796.05 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.
How can I contact Provention Bio?: Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Provention Bio - PRVB Stock Forecast, Price & News

Provention Bio MarketRank™ Forecast

Overall MarketRank™